Does TNON pay a dividend and is it safe?

Tenon Medical Inc. (TNON) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / TNON / dividends

SNOA (34) INBS (27) NVNO (33) WOK (51) ⌘ Pro Terminal →

Tenon Medical Inc. (TNON) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.93 -5.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.91

Tenon Medical Inc. (TNON) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TNON Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TNON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Tenon Medical Inc. (NASDAQ: TNON) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.93 (-5.85% 1D, market cap $5.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, TNON ranks #814 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TNON compare to SNOA and INBS in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), TNON carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 59.8%, and ROIC of -35.0%. By comparison, SNOA (Sonoma Pharmaceuticals Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and INBS (Intelligent Bio Solutions Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, TNON leads on earnings multiple (N/A) while TNON leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TNON?

▼

Per TNON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001560293), Tenon Medical Inc. generated $3.9M in revenue (+20.4% YoY), -$12.6M in net income, and -$11.0M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.91 (-1.24%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TNON)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY TNON SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 35.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.89-13.1% Next Q

Q2 (-2Q)

Grade E$2.51-14.7% Next Q

Q3 (-1Q)

Grade E$2.14-9.8% Next Q

Current

Grade E$1.93-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TNON Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TNON currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.50) and Max Pain ($2.03) forces dealer call-delta covering toward $47.77.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TNON• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TNON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (13% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $33,946

Est. Year-10 Shareholder Yield: $611/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.3K

Yr 1

$12.8K

Yr 2

$14.4K

Yr 3

$16.3K

Yr 4

$18.4K

Yr 5

$20.8K

Yr 6

$23.5K

Yr 7

$26.6K

Yr 8

$30.0K

Yr 9

$33.9K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TNON)

✓Walkthrough of TNON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TNON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -92.71%🛡️ HOLDING TREND SUPPORT

2026-11-03O $2.29H $2.29L $1.93C $1.93VOL 172.5K

RES: $4.71SUP: $1.48SMA50: $3.50SMA200: $16.77

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TNON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TNON Butterfly Map → + Track TNON →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +20.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TNON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TNON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TNON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TNON)

Health Care Rank #814 of 1015 ⚔️ SNOA vs TNON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TNON vs. SNOA, INBS, NVNO, WOK)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Tenon Medical Inc. (TNON) ranks #814 by composite RQD confidence (30/100, grade E) and #932 by equity capitalization ($5.5M). Within this direct 5-issuer industry benchmark cohort, TNON leads on earnings valuation at N/A trailing P/E, while TNON leads on capital efficiency and profitability with -35.0% ROIC and 59.8% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with TNON at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TNON ACTIVE Tenon Medical Inc.	E	30/100	—	59.8%	-35.0%	-5.85%	$5.5M	Benchmark Subject
SNOA Sonoma Pharmaceuticals Inc.	E	34/100	—	38.0%	-35.0%	0.00%	$5.3M	/snoa-vs-tnon →
INBS Intelligent Bio Solutions Inc.	E	27/100	—	40.8%	-35.0%	-5.68%	$5.8M	/inbs-vs-tnon →
NVNO enVVeno Medical Corporation	E	33/100	—	—	-35.0%	+2.08%	$4.7M	/nvno-vs-tnon →
WOK WORK Medical Technology Group LTD (Class A)	D	51/100	—	—	—	0.00%	$4.5M	/wok-vs-tnon →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001560293 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tenon Medical Inc. (TNON) reported GAAP revenue of $3.9M (+20.4% vs. FY2024 revenue of $3.3M , and +34.7% cumulative change since FY2023) , GAAP net income of -$12.6M, operating cash flow of -$10.7M, and free cash flow of -$11.0M (-9.5% YoY). On the balance sheet, TNON closed FY2025 with $10.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.9M	-$12.6M	-$10.7M	-$11.0M	$10.8M	—
FY2024 (FY)	2024-12-31	$3.3M	-$13.7M	-$9.9M	-$10.1M	$9.8M	—
FY2023 (FY)	2023-12-31	$2.9M	-$15.6M	-$12.2M	-$12.2M	—	—

3. TNON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TNON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TNON compare to SNOA and INBS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TNON?

Where is TNON trading relative to its 50-day, 200-day, and 52-week technical levels?

TNON last traded at $1.93 (-5.85% on volume of 61,387 shares), positioning the stock -44.86% below its 50-day simple moving average ($3.50) and -88.49% below its 200-day simple moving average ($16.77). Across its 52-week range of $2.05 to $45.50, TNON sits at the 0.0% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.69 to $2.17).

Direct Sub-Reports: TNON RQD Cockpit TNON 12M Forecast TNON Earnings & Move TNON Dividends & DRIP TNON Insiders & 13F TNON Whale Options TNON Profit Sankey TNON News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

TNON — Tenon Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Tenon Medical Inc. (TNON) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.93 (-5.85% 1D, market capitalization $5.5M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 59.8%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Tenon Medical Inc. (TNON) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. It is classified within these sector and industry categories. Per the market data, the company reports a gross margin of 59.8%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Tenon Medical Inc. (TNON) reported $3.9M in annual revenue (up from $3.3M in FY2024, +20.4% YoY) and -$12.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.9M revenue, -$15.6M net income) through FY2025, TNON scaled operating cash flow to -$10.7M and free cash flow to -$11.0M, backed by $10.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.05 – $45.50 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream or downstream dependencies, sector correlations beyond the Health Care/Medical-Dental Instruments classification, or second-order bottlenecks.

Key Question #1: Can TNON sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $3.9M and free cash flow of -$11.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is TNON's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TNON Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Tenon Medical Inc. (TNON) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TNON Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Tenon Medical, Inc. Sets Date for Third Quarter 2026 Earnings

Yahoo Finance report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Tenon Medical Expands ATM Offering to Boost Capital Flexibility

The Globe and Mail report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Tenon Medical, Inc. (TNON) Sets Q3 2026 Earnings Release for Nov. 12

TradingView report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Tenon Medical(R) Adds Eight New Patents Issued by the United States Patent and Trademark Office Through Q3 2026

Yahoo Finance report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An investor grants Tenon Medical (TNON) an offering waiver for a warrant with a $5.02 exercise price.

Stock Titan report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST kalkine.ca • 1d ago

Why Is Tenon Medical (NASDAQ:TNON) Penny Stock Down in a Month Despite Repeated Capital Raises?

kalkine.ca report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Tenon Medical Secures Waivers for ATM Offering Increase, Issues $5.02 Warrant

TradingView report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A single tool drills and prepares the joint in initial cases. Market release is targeted for early 2027.

Stock Titan report covering Tenon Medical Inc. (TNON) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TNON Bull vs. Bear Conversation Board — What's Your Call at $1.93?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TNON 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $2.58 (+25.9%)

📌 Pinned Debate

Revenue grew from $2.9M in FY 2023 to $3.9M in FY 2025 while the Altman Z-Score of 2.5 sits in the reported range.

Long TNON at $2.05 targeting $2.58. Revenue grew from $2.9M in FY 2023 to $3.9M in FY 2025 while the Altman Z-Score of 2.5 sits in the reported range.. Institutional whale score is 3/20 and the risk/reward vs. the $2.05 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

Both sides have a point here — TNON's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.68 (-18.0%)

Spot @ $2.05

ROIC of -35% and FCF of -$11.0M against cash of $3.8M point to a cash engine that is not self-funding and reliant on equity raises.

Here is the bear case nobody on the bull side wants to address on TNON: ROIC of -35% and FCF of -$11.0M against cash of $3.8M point to a cash engine that is not self-funding and reliant on equity raises.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.